Abstract
Objective: A novel, Supersaturable Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) has been prepared to improve the Dutasteride's poor aqueous solubility.
Methods: By adding Hydroxy Propyl Methyl Cellulose (HPMC) as a precipitation inhibitor to conventional SNEDDS, a supersaturable system was prepared. Firstly, the prepared SNEDDS played an important role in increasing the aqueous solubility and hence oral absorption due to nano-range size. Secondly, the S-SNEDDS found to be advantageous over SNEDDS for having a higher drug load and inhibition of dilution precipitation of Dutasteride. Formulated S-SNEDDS (F1-F9) ranged from 37.42 ± 1.02 to 68.92 ± 0.09 nm with PDI 0.219-0.34 and drug loading of over 95 percent. Results: The study of in-vitro dissolution revealed higher dissolution for S-SNEDDS compared to SNEDDS and Avodart soft gelatin capsule as a commercial product. In addition, higher absorption was observed for S-SNEDDS showing approximately 1.28 and 1.27 fold AUC (0-24h) and Cmax compared to commercial products. Therefore, S-SNEDDS has proven as a novel drug delivery system with a higher drug load, higher self-emulsification efficiency, higher stability, higher dissolution and pronounced absorption. Conclusion: In conclusion, S-SNEDDS could be a newly emerging approach to enhance aqueous solubility in many folds for drugs belonging to BCS Class II and IV and thus absorption and oral bioavailability.Keywords: Supersaturated Self-Nanoemulsifying Drug Delivery (S-SNEDDS), Hydroxy Propyl Methyl Cellulose (HPMC), Dutasteride, higher self-emulsification efficiency, Poor Aqueous Solubility, Nano-emulsion.
Graphical Abstract
[http://dx.doi.org/10.1016/j.ijpharm.2014.11.060] [PMID: 25437113]
[http://dx.doi.org/10.1016/j.ejps.2017.09.001] [PMID: 28889028]
[http://dx.doi.org/10.1002/jps.23858] [PMID: 24464737]
[http://dx.doi.org/10.1016/j.jddst.2015.05.004]
[http://dx.doi.org/10.1016/j.ijpharm.2013.10.044] [PMID: 24184217]
[http://dx.doi.org/10.1016/j.jconrel.2012.02.027] [PMID: 22405903]
[http://dx.doi.org/10.1016/j.ijpharm.2018.11.036] [PMID: 30448315]
[http://dx.doi.org/10.1248/bpb.34.278] [PMID: 21415541]
[http://dx.doi.org/10.5897/AJPP2013.2987]
[PMID: 26150696]
[http://dx.doi.org/10.3390/molecules200814684] [PMID: 26287134]
[http://dx.doi.org/10.4103/0976-500X.72350] [PMID: 21350616]
[http://dx.doi.org/10.1016/j.ijpharm.2014.11.060] [PMID: 25437113]
[http://dx.doi.org/10.5478/MSL.2014.5.3.79]
[http://dx.doi.org/10.3390/ijms160510821] [PMID: 25984604]
[http://dx.doi.org/10.1016/j.powtec.2016.02.023]
[http://dx.doi.org/10.1081/DDC-120028718] [PMID: 15089057]
[http://dx.doi.org/10.3109/1061186X.2010.525652] [PMID: 20973755]
[http://dx.doi.org/10.1208/s12249-009-9221-6] [PMID: 19444620]
[http://dx.doi.org/10.3797/scipharm.1201-06] [PMID: 23264948]